Breast Biopsy Devices Market is Expected to Reach $2.6 billion | MarketsandMarkets.

Chicago, Aug. 23, 2023 (GLOBE NEWSWIRE) -- In the near future, the Breast Biopsy Devices industry is poised to undergo significant advancements driven by innovative technologies and a growing emphasis on early and accurate breast cancer detection. Miniaturization and integration of cutting-edge imaging modalities, such as AI-assisted mammography and ultrasound, with biopsy devices will enhance precision and reduce invasiveness. Moreover, the integration of robotics and real-time imaging guidance will enable minimally invasive procedures, optimizing patient comfort and procedural efficiency. These developments will not only enhance diagnostic accuracy but also contribute to a broader adoption of regular screenings, ultimately leading to improved patient outcomes and a reduction in breast cancer mortality rates. As the industry converges with the broader trend of personalized medicine, the breast biopsy devices sector will play an increasingly pivotal role in tailoring treatment strategies and improving overall women's health.

Breast Biopsy Devices market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $2.6 billion by 2028, growing at a CAGR of 10.0% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Technological advancements and an increasing incidence of breast cancer, an increasing number of breast cancer screening programs, increasing demand for minimally invasive and non-invasive procedures, and growing awareness regarding early detection of breast cancer are the key factors driving the adoption of breast biopsy systems globally. Breast biopsy systems are essential for accurate and minimally invasive tissue sampling for diagnostic purposes. These systems enable guided and minimally invasive biopsy procedures, support various biopsy techniques, and assist in the localization of lesions for surgical planning when necessary. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805

Breast Biopsy Devices Market Scope:

Report Coverage	Details
Market Revenue in 2023	$1.6 billion
Estimated Value by 2028	$2.6 billion
Growth Rate	Poised to grow at a CAGR of 10.0%
Market Size Available for	2021–2028
Forecast Period	2023–2028
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Procedure, Technique, Application, End User, and Region
Geographies Covered	North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Report Highlights	Updated financial information / product portfolio of players
Key Market Opportunities	Emergence of liquid biopsy and promising clinical trials
Key Market Drivers	Increasing number of breast cancer screening programs

Breast Biopsy Devices market major players covered in the report, such as:

• Hologic Inc. (US)
• Danaher Corporation (US)
• Becton Dickinson, and Company (US)
• Argon Medical Devices (US)
• Merit Medical Systems (US)
• Menarini-Silicon Biosystems (Italy)
• Sterylab S.R.L (Italy)
• Guardant Health, Inc. (US)
• NeoGenomics (US)
• Sysmex Inostics (Germany)
• Biocept, Inc (US)
• Bio-Rad Laboratories, Inc. (US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Qiagen (Germany)
• Exact Sciences Corporation (US)
• and Among Others

Buy a Breast Biopsy Devices Industry Report (200 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=189011805

This report has segmented the global breast biopsy devices market based on Type, Procedure, Technique, Application, End User and Region.

Global Breast Biopsy Devices Market, by Type

• Biopsy Needles
• Guidance Systems
• Biopsy Tables
• Localization Wires
• Assay Kits
• Liquid Biopsy Instruments
• Others

Global Breast Biopsy Devices Market, by Procedure

• Needle Breast Biopsy
• Core-Needle Biopsy (CNB)
• Fine-Needle Aspiration Biopsy (FNAB)
• Vacuum-Assisted Biopsy (VAB)
• Open Surgical Breast Biopsy
• Excisional
• Incisional
• Liquid Breast Biopsy
• Circulating Tumor Cells
• Circulating Tumor DNA (CtDNA)
• Other Biomarkers

Global Breast Biopsy Devices Market, by Technique

• Image Guided Biopsy
• Mammo-Guided Stereotactic
• Ultrasound-Guided
• MRI-Guided
• Other Image-Guided Techniques
• Liquid Biopsy
• NGS based Biopsy
• PCR based Biopsy
• Microarray-based Biopsy

Global Breast Biopsy Devices Market, by Application

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

Global Breast Biopsy Devices Market, by End User

• Hospitals & Surgical Centers
• Breast Care Centers
• Imaging & Diagnostic Centers

Breast Biopsy Devices Market, by region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=189011805

The key stakeholders in the Breast Biopsy Devices market include:

• Biopsy needles and guidance system manufacturing companies
• Liquid biopsy assay kit manufacturers and suppliers
• Breast care facilities and imaging centers
• Cancer research centers
• Hospitals and surgical centers
• Ambulatory care centers
• Research laboratories and academic institutes
• Contract research organizations
• Breast biopsy software providers
• Medical device distributors and suppliers
• Market research and consulting firms

Recent Developments:

• Hologic, Inc, an innovative medical technology company primarily focused on improving women’s health, announced today that it has completed the purchase of SOMATEX Medical Technologies GmbH; the deal size is $64 million.
• In 2022 Danaher Corporation launched Mammotome Revolve EX Dual Vacuum-Assisted Breast Biopsy System, the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems.
• Argon Medical Devices announced the launch of the SuperCore advantage semi-automatic biopsy instrument’s newest addition to its soft tissue biopsy product portfolio in the United States. The next-generation soft tissue biopsy instrument provides a superior volume of tissue samples. Collecting more tissue volume may increase the likelihood of an accurate diagnosis.

Frequently Asked Questions (FAQs) of Breast Biopsy Devices Market:

Question 1: What is the expected addressable market value of the global breast biopsy market over a six-year period?
Answer: The global breast biopsy market is expected to reach USD 2.6 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 10.0% from 2023 to 2028.

Question 2: Which segment based on type is expected to garner the highest traction within the breast biopsy market?
Answer: Based on the type, the biopsy needles segment is expected to grow at the highest rate.

Question 3: What strategies are top market players adopting to penetrate emerging regions?
Answer: The major players in the market use partnerships, expansion, and product launches as important growth tactics.

Question 4: What are the major factors expected to limit the growth of the breast biopsy market?
Answer: The availability of alternate imaging technologies and high equipment cost is expected to limit the growth of the breast biopsy market.

Question 5: Which are the major companies in the breast biopsy market?
Answer: The major companies in the market are Hologic Inc. (US), Danaher Corporation (US), Becton Dickinson, and Company (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Guardant Health, Inc. (US), NeoGenomics (US), Sysmex Inostics (Germany), Sterylab S.R.L. ( Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Exact Sciences Corporation (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=189011805

Report Objectives:

• To define, describe, and forecast the breast biopsy market by Type, Procedure, Technique, Application, End User and Region
• To provide detailed information regarding major factors influencing the market growth (drivers, restraints, opportunities, and industry-specific challenges)
• To strategically analyze micro markets with respect to their individual growth trends, prospects, and contributions to the market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast revenue of the market segments with respect to five regions: North America (US and Canada), Europe (Germany, France, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America), and the Middle East & Africa.
• To strategically profile the key players and comprehensively analyze their market shares and core competencies
• To track and analyze competitive developments in the breast biopsy market, such as product launches and product enhancements; agreements, partnerships, and collaborations; acquisitions; and R&D developments.

Related Reports:

Cancer Diagnostics Market

Aspiration Needles Market

Liquid Biopsy Market

Womens Health Diagnostics Market

Breast Imaging Market

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biopsy-devices-breast-biopsy-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/biopsy-devices-breast-biopsy.asp

            About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com